BP-C2

The company’s second product is BP-C2, which is based on BP-Cx-1 combined with molybdenum salts.  BP-C2 is in preclinical development for prevention of side effects arising from cancer radiotherapy, nuclear radiation and irradiation at large.

Molybdenum is a known cofactor for several human enzymes involved in the metabolism and breakdown of a number of potential harmful substances in the body.  Furthermore, BP-C2 acts as a scavenger of free radicals, and the BP-Cx-1 component has important immune stimulatory effects.

Animal models have demonstrated that BP-C2 is capable of significantly reducing mortality in mice subjected to very high doses of radiation.